|
Market Closed -
Hong Kong S.E.
08:08:15 02/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.4300 HKD | -1.15% |
|
-6.52% | -14.00% |
| 08-28 | Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-24 | Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) | CI |
Company Valuation: Mabpharm Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 3,646 | 3,360 | 1,587 | 1,722 | 1,085 | 1,853 |
| Change | - | -7.86% | -52.77% | 8.51% | -36.99% | 70.77% |
| Enterprise Value (EV) 1 | 3,202 | 3,325 | 1,710 | 1,831 | 1,307 | 2,070 |
| Change | - | 3.84% | -48.58% | 7.11% | -28.61% | 58.37% |
| P/E | -19.7x | -11.5x | -7.53x | -8.23x | -8.48x | 44.9x |
| PBR | 4.14x | 5.58x | 3.96x | 8.4x | 12.2x | 11.8x |
| PEG | - | -0.2x | 0.3x | 11.85x | 0.2x | -0x |
| Capitalization / Revenue | 160x | 40.5x | 28.4x | 19.8x | 4.2x | 2.87x |
| EV / Revenue | 141x | 40.1x | 30.6x | 21x | 5.06x | 3.2x |
| EV / EBITDA | -21.8x | -12.7x | -9.31x | -12.2x | -19.8x | 34.9x |
| EV / EBIT | -19.6x | -11.2x | -7.56x | -9.07x | -10.9x | 431x |
| EV / FCF | -19.4x | -10x | -6.95x | -23.6x | -8.64x | 18,952x |
| FCF Yield | -5.17% | -9.96% | -14.4% | -4.24% | -11.6% | 0.01% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0448 | -0.0707 | -0.0511 | -0.0508 | -0.031 | 0.01 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 22.78 | 82.88 | 55.92 | 87.16 | 258.2 | 646.1 |
| EBITDA 1 | -147.2 | -262.8 | -183.7 | -150.1 | -65.94 | 59.28 |
| EBIT 1 | -163.4 | -297.5 | -226.3 | -202 | -119.7 | 4.803 |
| Net income 1 | -184.6 | -291.7 | -210.8 | -209.4 | -127.9 | 57.13 |
| Net Debt 1 | -444.5 | -35.13 | 122.7 | 109.2 | 222.2 | 217.5 |
| Reference price 2 | 0.8841 | 0.8147 | 0.3848 | 0.4175 | 0.2631 | 0.4493 |
| Nbr of stocks (in thousands) | 4,124,080 | 4,124,080 | 4,124,080 | 4,124,080 | 4,124,080 | 4,124,080 |
| Announcement Date | 21/04/21 | 21/04/22 | 20/04/23 | 18/04/24 | 22/04/25 | 27/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 229M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -70.14x | 13.02x | -68.47x | -.--% | 24.7B | |
| Average | 17.50x | 28.01x | 7.09x | 0.34% | 39.46B | |
| Weighted average by Cap. | 21.73x | 26.34x | 11.23x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2181 Stock
- Valuation Mabpharm Limited
Select your edition
All financial news and data tailored to specific country editions
